Results 151 to 160 of about 22,335 (252)

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake   +14 more
wiley   +1 more source

Circadian disruption elicits sex‐specific gut microbiota, endocannabinoidome, and lipid mediator responses

open access: yesThe FEBS Journal, EarlyView.
Circadian disruption via constant light induces sex‐specific remodeling of the microbiome, lipid mediators, and immune responses. Females exhibit broader gut microbiota alterations, reduced jejunal oxylipins, increased hypothalamic N‐acylethanolamines, and a more inflammatory cytokine profile. Muscle responses are sex‐ and fiber type‐dependent: females
Pejman A. Pashaki   +7 more
wiley   +1 more source

Bringing Gene Therapy Into Real World Clinical Practice

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach   +2 more
wiley   +1 more source

The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease. [PDF]

open access: yesNat Commun
Siddiqui MS   +17 more
europepmc   +1 more source

The gut-liver axis in progressive steatotic liver disease

open access: yes
The gut-liver axis regulates metabolic homeostasis, with bile acids (BAs) serving as key signalling molecules. BA dysregulation is implicated in metabolic dysfunction-associated steatotic liver disease (MASLD)and metabolic dysfunction- and alcohol-associated liver disease (MetALD), yet consistent identification of BA markers and their mechanistic roles
Louca, Panayiotis   +11 more
openaire   +1 more source

Home - About - Disclaimer - Privacy